Honn Kenneth V, Aref Amer, Chen Yong Q, Cher Michael L, Crissman John D, Forman Jeffrey D, Gao Xiang, Grignon David, Hussain Maha, Porter Arthur T, Pontes Edson J, Powell Isaac, Redman Bruce, Sakr Wael, Severson Richard, Tang Dean G, Wood David P
Wayne State University, Cancer Biology Division, Department of Radiation Oncology, Detroit, USA.
Pathol Oncol Res. 1996;2(3):191-211. doi: 10.1007/BF02903527.
Diagnostic and prognostic markers for prostatic cancer (PCa) include conventional protein markers (e.g., PAP, PSA, PSMA, PIP, OA-519, Ki-67, PCNA, TF, collagenase, and TIMP 1), angiogenesis indicator (e.g., factor VIII), neuroendocrine differentiation status, adhesion molecules (E-cadherin, integrin), bone matrix degrading products (e.g., ICPT), as well as molecular markers (e.g., PSA, PSMA, p53, 12-LOX, and MSI). Currently, only PSA is used clinically for early diagnosis and monitoring of PCa. The histological differential diagnosis of prostatic adenocarcinoma includes normal tissues such as Cowper's gland, paraganglion tissue and seminal vesicle or ejaculatory duct as well as pathological conditions such as atypical adenomatous hyperplasia, atrophy, basal cell hyperplasia and sclerosing adenosis. A common PCa is characterized by a remarkable heterogeneity in terms of its differentiation, microscopic growth patterns and biological aggressiveness. Most PCa are multifocal with signi ficant variations in tumor grade between anatomically separated tumor foci. The Gleason grading system which recognizes five major grades defined by patterns of neoplastic growth has gained almost uniform acceptance. In predicting the biologic behavior of PCa clinical and pathological stages are used as the major prognostic indicators. Among the cell proliferation and death regulators androgens are critical survival factors for normal prostate epithelial cells as well as for the androgen-dependent human prostatic cancer cells. The androgen ablation has been shown to increase the apoptotic index in prostatic cancer patients and castration also promotes apoptotic death of human prostate carcinoma grown in mice. The progression of PCa, similarly to other malignancies, is a multistep process, accompanied by genetic and epigenetic changes, involving phenomenons as adhesion, invasion and angiogenesis (without prostate specific features).
前列腺癌(PCa)的诊断和预后标志物包括传统蛋白质标志物(如前列腺酸性磷酸酶、前列腺特异性抗原、前列腺特异性膜抗原、前列腺抑制素、OA-519、Ki-67、增殖细胞核抗原、转铁蛋白、胶原酶和基质金属蛋白酶组织抑制因子1)、血管生成指标(如因子VIII)、神经内分泌分化状态、黏附分子(E-钙黏蛋白、整合素)、骨基质降解产物(如I型胶原羧基末端肽)以及分子标志物(如前列腺特异性抗原、前列腺特异性膜抗原、p53、12-脂氧合酶和微卫星不稳定性)。目前,临床上仅将前列腺特异性抗原用于前列腺癌的早期诊断和监测。前列腺腺癌的组织学鉴别诊断包括正常组织,如尿道球腺、副神经节组织和精囊或射精管,以及病理状况,如非典型腺瘤样增生、萎缩、基底细胞增生和硬化性腺病。常见的前列腺癌在分化、微观生长模式和生物学侵袭性方面具有显著的异质性。大多数前列腺癌是多灶性的,在解剖学上分离的肿瘤灶之间肿瘤分级存在显著差异。识别由肿瘤生长模式定义的五个主要级别的Gleason分级系统已几乎得到一致认可。在预测前列腺癌的生物学行为时,临床和病理分期用作主要的预后指标。在细胞增殖和死亡调节因子中,雄激素是正常前列腺上皮细胞以及雄激素依赖性人类前列腺癌细胞的关键存活因子。雄激素去除已被证明可增加前列腺癌患者的凋亡指数,去势也可促进在小鼠体内生长的人前列腺癌的凋亡死亡。与其他恶性肿瘤类似,前列腺癌的进展是一个多步骤过程,伴随着基因和表观遗传变化,涉及黏附、侵袭和血管生成等现象(无前列腺特异性特征)。